Privacy preference

MEDtalks would like to keep you informed about the content that is most relevant to you. Click here for more information.


E-learning: Quarterly Focus on Hemato-Oncology | Highlights in AML 2018

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not always have sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks Hematology has developed a program format: the Quarterly Focus. This innovative program brings an expert panel and authors of relevant, selected publications together to explain and discuss the new data.

Three high-impact, recent international publications on two main topics in AML will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the possibility to gain more insight into the selected publications. During this live broadcast you will have the unique opportunity to interact with our expert panel and the authors and ask them your questions.

The studio expert panel consists of:

Prof. Gert Ossenkoppele, MD, PhD, hematologist, VUmc Amsterdam, The Netherlands

Bas Wouters, MD, PhD, hematologist, ErasmusMC Rotterdam, The Netherlands

Peter Valk, PhD, molecular biologist in hematology, ErasmusMC Rotterdam, The Netherlands

Live video guests:

Courtney Dinardo, MD, hemato-oncologist, MD Anderson Cancer Center, Houston, US

Eytan Stein, MD, hemato-oncologist, MSKCC, New York, US

Prof. Christian Thiede MD, PhD, professor in molecular hematology, Universitätsklinikum Dresden, Germany

  • Invited speakers

  • Prof. Gert Ossenkoppele, MD, PhD

    hematologist

    Amsterdam UMC (VUmc)

  • Bas Wouters, MD, PhD

    hematologist

    Erasmus MC, Rotterdam

  • Peter Valk, PhD

    molecular biologist

    Erasmus MC, Rotterdam

  • Sponsors

    This program is editorially independent and is financially made possible by

Related items

Congresnieuws 17/06/2012

EHA 2012 | News Program June 17

The second News Program of Hematology TV from EHA 2012 June 17. Multiple Myeloma Interview Hodgkins Lymphoma Acute Myeloid Leukemia

Congresnieuws 08/12/2014

ASH 2014 Highlight 3 - Leukemia

Highlight on leukemia: Prof. Dr. med. Uwe Platzbecker tells if ATRA+arsenicumtrioxide should become the new standard care for non-high risk APML by illustrating the Italian-German APL0406 trial. Ian Flinn MD PhD provides an overview on novel therapies for CLL. Prof. Dr. Michele Baccarani discusses whether imatinib remains the standard therapy for CML by elaborating on the DASISION, SPIRIT-2 and EPIC trails. Prof. Dr. Rien van Oers concludes with the PROLONG trial which investigates ofatumumab maintenance therapy in R/R CLL.

Congresnieuws 12/06/2014

EHA 2014 - News Report 1

EHA 2014 – News Report 1 on: CLL by Prof. Stephan Stilgenbauer, the José Carreras Lecture ‘Genetics to guide management of patients with AML by Prof. Hartmut Döhner, the pathophysiology of auto-immune hemolytic anemia by Prof. Hannah Tamary and Stem Cell Transplantation: focus on chronic GvHD by Prof William Arcese.

Quarterly focus 22/03/2018

Quarterly Focus on Hemato-Oncology | Highlights in AML

Publications in peer-reviewed journals are a major source for keeping up with the latest developments in your field. However, you may not have always sufficient time to study (difficult) publications thoroughly and to determine the impact on your clinical practice. To support you, MEDtalks.eu has developed a new program format, the 'Quarterly Focus, which brings together an expert panel and the authors of relevant, selected publications in an innovative way to explain and discuss the new data. The selection for the first edition of Quarterly Focus on Hemato-Oncology has been made by prof. dr. Gert Ossenkoppele, VUmc Amsterdam, Netherlands. Three pivotal, international publications from the past few months will be clarified by one of the authors and will be thoroughly discussed by an expert panel including the author. The program will give you the unique possibility to gain more insight into the selected publications and to interact with the expert panel and the authors. The expert panel consists of: Prof. Gert Ossenkoppele, MD, hematologist, VUmc, Amsterdam, Netherlands; Prof. Gerwin Huls, MD, hematologist, UMCG, Groningen; Netherlands; Peter Valk, Ph.D., molecular biologist, Erasmus MC, Rotterdam, Netherlands. Selected publications Quarterly Hemato-Oncology: Midostaurin plus chemotherapy for acute myeloid leukemia with FLT mutation N Engl J Med 2017 Prof. Richard Schlenk, MD, hematologist TP53 and decitabine in AML and myelodysplastic syndromes N Engl J Med 2016 Dr. John S. Welch, MD, Ph.D., hematologist Precision Oncology in acute myeloid leukemia using a knowledge bank approach. Nature Genetics, January 2017 Elli Papaemmanuil, Ph.D., molecular geneticist Accreditation: This program will be submitted for accreditation at the EBAH and Dutch NIV.

Congresnieuws 25/06/2017

Clinical updates from the EHA 2017 part 2

The 22nd European Hematology Association (EHA) took place in Madrid, Spain, on 22-25 June 2017. An international multidisciplinary panel discussed a selection of topics and new data on hematology during a live program. They gave an answer to what this newly acquired knowledge means for clinical practice. Topics Immunotherapy for childhood ALL CML treatment in children and adults Treatment reduction in Hodgkin Lymphoma Fertility preservation The role of the microbiome to improve survival after allogeneic stem cell transplantation Prof. Harry Schouten, MD – hematologist, Maastricht UMC+, Maastricht, The Netherlands Speakers Thamer Sliwa, MD – hematologist, Hanusch Krankenhaus, Vienna, Austria Prof. Michel Zwaan, MD – pediatric hematologist, EMC, Rotterdam, The Netherlands Moderator Prof. Harry Schouten, MD – hematologist, Maastricht UMC+, Maastricht, The Netherlands

Congresnieuws 17/06/2012

EHA 2012 | News Program June 17

The second News Program of Hematology TV from EHA 2012 June 17. Multiple Myeloma Interview Hodgkins Lymphoma Acute Myeloid Leukemia

Congresnieuws 08/12/2014

ASH 2014 Highlight 3 - Leukemia

Highlight on leukemia: Prof. Dr. med. Uwe Platzbecker tells if ATRA+arsenicumtrioxide should become the new standard care for non-high risk APML by illustrating the Italian-German APL0406 trial. Ian Flinn MD PhD provides an overview on novel therapies for CLL. Prof. Dr. Michele Baccarani discusses whether imatinib remains the standard therapy for CML by elaborating on the DASISION, SPIRIT-2 and EPIC trails. Prof. Dr. Rien van Oers concludes with the PROLONG trial which investigates ofatumumab maintenance therapy in R/R CLL.